Ambros Therapeutics takes neridronate public through Werewolf merger as $150m backs Phase 3 CRPS trial
The all-stock transaction values Ambros Therapeutics at $500 million and pairs its pivotal neridronate programme with a $150 million financing designed to fund development through Phase 3 data and an FDA filing.